MA44864A - Trithérapie pour le traitement d'une maladie intestinale inflammatoire - Google Patents
Trithérapie pour le traitement d'une maladie intestinale inflammatoireInfo
- Publication number
- MA44864A MA44864A MA044864A MA44864A MA44864A MA 44864 A MA44864 A MA 44864A MA 044864 A MA044864 A MA 044864A MA 44864 A MA44864 A MA 44864A MA 44864 A MA44864 A MA 44864A
- Authority
- MA
- Morocco
- Prior art keywords
- tritherapy
- treatment
- intestinal disease
- inflammatory intestinal
- inflammatory
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title 1
- 208000028774 intestinal disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331813P | 2016-05-04 | 2016-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44864A true MA44864A (fr) | 2019-03-13 |
Family
ID=58710089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044864A MA44864A (fr) | 2016-05-04 | 2017-05-04 | Trithérapie pour le traitement d'une maladie intestinale inflammatoire |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10918716B2 (OSRAM) |
| EP (1) | EP3452070A1 (OSRAM) |
| JP (2) | JP7162533B2 (OSRAM) |
| MA (1) | MA44864A (OSRAM) |
| WO (1) | WO2017192867A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101875155B1 (ko) | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| WO2017192867A1 (en) | 2016-05-04 | 2017-11-09 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating inflammatory bowel disease |
| MA45245A (fr) | 2016-06-12 | 2019-04-17 | Millennium Pharm Inc | Méthode de traitement de maladie intestinale inflammatoire |
| EP3956358A4 (en) * | 2019-04-17 | 2023-01-25 | Millennium Pharmaceuticals, Inc. | COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR |
| EP4068295B1 (en) * | 2021-03-29 | 2025-04-30 | Siemens Healthineers AG | Clinical decision support system for estimating drug-related treatment optimization concerning inflammatory diseases |
| WO2022266302A1 (en) * | 2021-06-17 | 2022-12-22 | Prometheus Laboratories Inc. | Systems and methods for improved targeted therapy |
| CN113402583B (zh) * | 2021-06-19 | 2023-03-21 | 江西农业大学 | Qgk三肽及其应用 |
| CN114225025B (zh) * | 2021-12-29 | 2022-07-26 | 贵州酵德生物科技有限公司 | 含有益生菌的制剂在治疗肠胃疾病中的应用 |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT808367E (pt) | 1995-02-10 | 2007-10-22 | Millennium Pharm Inc | Adressinas vasculares da mucosa e suas utilizações |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| AU2006316629A1 (en) | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with alpha 4 beta 7 integrin |
| KR101875155B1 (ko) | 2011-05-02 | 2018-07-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| WO2017192867A1 (en) | 2016-05-04 | 2017-11-09 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating inflammatory bowel disease |
-
2017
- 2017-05-04 WO PCT/US2017/031089 patent/WO2017192867A1/en not_active Ceased
- 2017-05-04 US US16/098,572 patent/US10918716B2/en active Active
- 2017-05-04 MA MA044864A patent/MA44864A/fr unknown
- 2017-05-04 JP JP2018558238A patent/JP7162533B2/ja active Active
- 2017-05-04 EP EP17724180.9A patent/EP3452070A1/en active Pending
-
2021
- 2021-01-19 US US17/152,585 patent/US12246064B2/en active Active
-
2022
- 2022-07-01 JP JP2022107008A patent/JP7474287B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7474287B2 (ja) | 2024-04-24 |
| US12246064B2 (en) | 2025-03-11 |
| US20210252141A1 (en) | 2021-08-19 |
| WO2017192867A1 (en) | 2017-11-09 |
| JP7162533B2 (ja) | 2022-10-28 |
| US20190142938A1 (en) | 2019-05-16 |
| JP2022141713A (ja) | 2022-09-29 |
| JP2019514974A (ja) | 2019-06-06 |
| US10918716B2 (en) | 2021-02-16 |
| EP3452070A1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| EP3728271A4 (en) | MACROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3431105A4 (en) | MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER | |
| EP3790867A4 (en) | KDM1A INHIBITORS FOR DISEASE TREATMENT | |
| EP3019491A4 (en) | KINASEHEMMER FOR THE TREATMENT OF DISEASES | |
| EP3402533A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | |
| EP3452166A4 (en) | INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3718561A4 (en) | Therapy for inflammatory bowel disease | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3291815A4 (en) | METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE | |
| EP3393468A4 (en) | METHOD FOR TREATING AN IMMUNE WEAKNESS | |
| EP3737361A4 (en) | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES | |
| MA41052A (fr) | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii | |
| EP3528852A4 (en) | METHOD AND COMPOSITIONS FOR TREATING MORBUS FABRY | |
| EP3419622A4 (en) | TREATMENT OF NEURODEGENERATIVE EYES DISEASES WITH PRIDOPIDINE | |
| EP3432892A4 (en) | USEFUL MANNOSE-DERIVED ANTAGONISTS FROM FIMH FOR THE TREATMENT OF DISEASES | |
| MA49131A (fr) | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie | |
| MA47395A (fr) | Méthode pour le traitement d'une maladie neurologique | |
| EP3641811A4 (en) | IMMUNPRIVILEGATED BIOACTIVE KIDNEY CELLS FOR TREATMENT OF KIDNEY DISEASE | |
| EP3440094A4 (en) | MITOCHONDRIAL TDP-43 LOCALIZATION TREATMENT FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| EP3766497A4 (en) | Drug for treating cough | |
| EP3443962A4 (en) | Quinoline derivative for the treatment of gastric cancer | |
| MA53268A (fr) | Mini-gde pour le traitement de la maladie de stockage du glycogène iii |